Weight and visceral fat control
Ob-X™
- Brand nameOb-X™ (Melissa officinalis L, Morus alba L.)
- OriginKorea
- Strong pointDecrease of visceral fat through angiogenic inhibitory 3 cases of Human clinical trial completed, South Korea, USA, Japan, China, Canada, and Europe patents
Result of Clinical Trial
- Inje University Seoul Paik Hospital
- 53 Subjects, for 12 weeks, randomized, double-blind, placebo controlled study
Decrease of waist-circumference and body weight
Decrease of visceral fat and atherogenic index
- Severance Hospital, YONSEI University
- 25 Subjects, for 12 weeks, randomized, double-blind, placebo controlled study